Skip to content
DataLookout
Menu

NCT07301138

BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened
    • Eligibility criteria expanded, about 17 words
    • Site details revised
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

MRD negativity rate
Timeframe: At the end of Cycle 2 of BEBT-908 combined chemotherapy treatment (each cycle is 28 days)

Secondary (4)

Overall survival (OS)
Relapse-free survival (RFS)
Progression-Free Survival (PFS)
Incidence of adverse events

Arms and interventions

intervention groupExperimental

* BEBT-908 for Injection, dosage of administration:12.3mg/m2,frequency and duration of administration: on the 1st,3rd,5th,8th, 10th and 12th days of each cycle and 28 days as a cycle. * Cyclophosphamide Injection, dosage of administration: 150 mg/m2 every 12 hours on days 1 to 3 of odd cycles, and 28 days as a cycle. * Vincristine Injection, dosage of administration: 1.4mg/m2 on day 4 and 11 of odd cycles, and 28 days as a cycle. * Dexamethasone Injection, dosage of administration: 20 mg per day on days 1 to 4 and 11 to 14 of odd cycles, and 28 days as a cycle. * Methotrexate Injection, dosage of administration: 1g/m2 on day 1 of even cycles, and 28 days as a cycle. * Cytarabine Injection, dosage of administration: 0.5 g/m2 given every 12 hours on day 2 and 3 of even cycles, and 28 days as a cycle.

Drugs: BEBT-908, Cyclophosphamide, Vincristine, Dexamethasone, Methotrexate, Cytarabine

Sites

1 site in 1 country

  • Ruijin Hospital, Shanghai Jiaotong University School of MedicineShanghai, Shanghai Municipality, China